Organisation
Scientific coordination of the CPER Resist-omics project
Pr David Launay
University Professor, Hospital Practitioner, specialist in internal medicine, Head of the Clinical Immunology Unit at Lille University Hospital, Director of the University Hospital Federation for Precision Medicine in Chronic Inflammatory Diseases (FHU PRECISE), Co-Director of the Reference Centre for Rare Systemic Autoimmune and Autoinflammatory Diseases in Adults in the North, North-West, Mediterranean and Guadeloupe (CeRAINOM) and of the Joint Research Unit U1286 INFINITE.
David Launay has authored over 500 publications in the field of inflammatory diseases.
Dr Nathalie Mielcarek
Research Director at the French National Institute of Health and Medical Research (Inserm), Deputy Director of the Lille Centre for Infection and Immunity (CIIL), Director of the Mycobacteria and Bordetella Research Team (RMB) within the CIIL, and Head of International Relations at the Pasteur Institute in Lille.
Nathalie Mielcarek is also co-inventor of a portfolio of patents relating to the development of BPZE1, a nasal vaccine against whooping cough, licensed to ILIAD Biotechnologies (USA) and currently in clinical development.
Pr Benoît Deprez
Scientific Director of the Pasteur Institute in Lille, Professor at the Faculty of Pharmacy, Director of the Inserm Unit U1177 ‘Drugs & Molecules for Living Systems’, member of the National Academy of Pharmacy and founder of the company Apteeus.
Benoît Deprez is the author of over 140 publications and 10 patent families, three of which have been licensed.
The operational team
For the coordination and monitoring of programmes :
- David Launay (Inserm, Lille University Hospital, University of Lille), Nathalie Mielcarek (Inserm), Benoît Deprez (University of Lille)
- Fabienne Jean (Institut Pasteur de Lille)
- Anne-Sophie Yribarren, Project Manager for CPER Resist-omics and CPER TecSanté (University of Lille)
